ライフサイエンスコーパス: transplant

1 uppression (excluding the first 5 days after transplant).

2 ll US centers including our own (open kidney transplant).

3 ng and management protocols before and after transplant.

4 erived KS in the recipient of a liver-kidney transplant.

5 overall survival in animals that received a transplant.

6 dialysis (DGF-D) in the first 72 hours after transplant.

7 order (PTSD) symptoms, and QOL 6 months post-transplant.

8 cord and European Group for Blood and Marrow Transplant.

9 rimary endpoint was Kaplan-Meier survival to transplant.

10 tion on depression and PTSD at 6 months post-transplant.

11 onal 28 organs were possibly appropriate for transplant.

12 nal Assessment of Cancer Therapy-Bone Marrow Transplant.

13 nerics in individuals with a kidney or liver transplant.

14 lls, arguably persisting for the life of the transplant.

15 drimembral amputations and a previous kidney transplant.

16 rticularly those who have received stem cell transplants.

17 ntially improve graft survival in DCD kidney transplants.

18 the ABOi and 98% in 50 compatible pediatric transplants.

19 r to that of HLA well-matched deceased donor transplants.

20 anges over time when corals are reciprocally transplanted.

21 sixty-five adults with PCKD received kidney transplants (303 tx alone, 161 simultaneous, 27 pre).

22 ns from donors with ITP resulted in 49 organ transplants (31 kidney, 14 liver, four heart), with only

23 urgency experience varying opportunities for transplants across the United States.

24 labour intensive and costly methods, such as transplanting adult shoots, if disturbances are moderate

25 Transplant albumin, day-1 aspartate aminotransferase (AS

26 reduce the geographic heterogeneity in liver transplant allocation, the United Network of Organ Shari

27 Tailored immunosuppression when transplanting an old kidney may be useful, but no formal

28 he United Network for Organ Sharing/Standard Transplant Analysis and Research database identified 12,

29 ter brain death (DBD), and living donor (LD) transplants, analyzing 3-year patient and renal allograf

30 munocompromised individuals, including organ transplant and AIDS patients.

31 safe and effective for patients after renal transplant and is a promising treatment regimen for erad

32 There were no significant differences in transplant and pretransplant covariates between inductio

33 Rates for death or double-lung transplant and the composite rates for death, double-lun

34 both; (31 [70%]) had received an autologous transplant, and (30 [62%]) had high-risk cytogenetics.

35 bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfusion.

36 Around 1600 deceased donor livers are transplanted annually.

37 patients who are urgently requiring a liver transplant are prioritized.

38 severe dilated cardiomyopathy that underwent transplant, as well as in his affected father.

39 -dependent endothelial cell injury in kidney transplants, as assessed by expression of endothelial ce

40 included 469 consecutive patients who had a transplant assessment between 2011 and 2014.

41 Transplant-associated thrombotic microangiopathy (TA-TMA

42 with low-dose TBI after haplocord stem cell transplant assures good engraftment and leads to accepta

43 l candidates with MELD scores >/=35 who were transplanted at a median MELD score of 39 (interquartile

44 ney transplant recipients who received their transplant between Jan 1, 2007, and Dec 31, 2013, and we

45 ansplantation recipients aged 2 to 40 years, transplanted between October 1999 and January 2007, were

46 ancreas and kidney and pancreas after kidney transplants between January 1994 and July 2013.

47 omycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

48 nt are living longer with MCSs for bridge to transplant (BTT) and destination therapy (DT).

49 er donation after cardiac death (DCD) kidney transplants, but the impact of DGF on graft outcomes is

50 espan was higher in Ki/SPK compared with SLK transplants by 0.99 years in the Model for End-stage Liv

51 Setting strict body mass index cutoffs for transplant candidacy remains controversial, with limited

52 of a positive crossmatch as a function of a transplant candidate's unacceptable HLA antigens.

53 explanted (recovered patients), and 24 heart transplant candidates (HTx)-and 97 healthy controls perf

54 Kidney transplant candidates (KTCs) must provide informed conse

55 dentify acceptable mismatches for sensitized transplant candidates but also to identify more suitably

56 Among pediatric liver transplant candidates in the US, children who died or we

57 Liver transplant candidates with advanced renal dysfunction an

58 immunosuppression and other aspects of post-transplant care.

59 , little is known about the direct impact of transplanted cells on injured brain tissue.

60 Indeed, these transplanted cells successfully remyelinate axons, but u

61 Targeted efforts to improve transplant center participation in paired kidney exchang

62 re (DT) in a level 1 trauma center and large transplant center.

63 Despite transplant centers accepting recipients who are older wi

64 -group trial conducted in 19 French academic transplant centers and involving participants who were a

65 A significant proportion of kidney transplant centers are identified as low performing with

66 oupled with variation between the 7 UK liver transplant centers in risk appetite.

67 on Polyomavirus Nephropathy, comprising nine transplant centers in the United States and Europe.

68 cost concerns prior to donation might allow transplant centers to target financial support intervent

69 January 2013 to July 2015 among adult kidney transplant centers.

70 lone transplants performed in all 19 English transplant centres between 2003 and 2014.

71 Chronic allograft injury (transplant chronic glomerulopathy [cg] or chronic lesion

72 Transplantation Society convened a group of transplant clinical trial experts to address these probl

73 tested negative for HCV were less frequently transplanted compared with the standard risk donors (3.9

74 These findings indicate that transplant connectivity is largely dictated by the circu

75 DD from the Improving DCDD Outcomes in Liver Transplant consortium demonstrates significant differenc

76 dently associated with higher 1-year post-LT transplant costs were older age, poor functional status

77 a notable reduction in the quality of livers transplanted, coupled with variation between the 7 UK li

78 nor hematopoietic transplantation using post-transplant cyclophosphamide was originally described usi

79 cant differences in baseline demographics or transplant data among the 4 neutralizing serostatus grou

80 Liver transplant data from the Austin Hospital, Melbourne, Aus

81 d 2012 were extracted from the French kidney transplant database.

82 On post-transplant days 3-5, the treatment group had lower value

83 parameters analyzed were: HLA antibodies at transplant, de novo donor-specific antibodies (DSA), ant

84 raft failure or primary nonfunction at liver transplant decision time assists utilization of scarce r

85 in THPO cause BMF, which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechani

86 lammation and structural deterioration limit transplant durability.

87 Genome transplant dynamics (GTD) quantifies donor-derived cfDNA

88 remain much higher than the number of organs transplanted each year.

89 organ shortage, preservation of average post-transplant eGFR will require sustained improvement in im

90 Transplant-eligible patients with relapsed/refractory HL

91 detect and quantify Treg effects in a given transplant environment.

92 tly established that HIV-1 can infect kidney transplant epithelial cells in the absence of detectable

93 dings demonstrate the biomarker potential of transplant exosome characterization for providing a noni

94 Here, we used reciprocal transplant experiments along a shallow water volcanic pC

95 The top 15 donor, recipient, and transplant factors influencing the outcome of graft fail

96 festations suggests that patient, donor, and transplant factors modulate the phenotype.

97 egression adjusted for recipient, donor, and transplant factors.

98 cted all-cause mortality among patients with transplant failure reentering HD.

99 tion is the most common cause of solid organ transplant failure.

100 ve chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation

101 body mass index was 25.5 +/- 5.2 in patients transplanted for IBDI.

102 This study sought to describe transplant-free survival and explore relationships betwe

103 Interim transplant-free survival over 12 years in this Fontan co

104 ed mortality with a competing risk model and transplant-free survival with a Cox proportional hazards

105 nd organ failure can safely receive an organ transplant from an HIV uninfected donor.

106 Network of Organ Sharing database that were transplanted from January 1, 2007, to September 30, 2015

107 survival was analyzed and survival rates of transplants from poorly matched living donors were compa

108 hich has implications for islet survival and transplanted graft longevity.

109 12.5] years), and 2980 patients in the renal transplant group (27.3% women; 72.7% men; mean [SD] age,

110 se of TCS devices in children as a bridge to transplant has risen rapidly in recent years, led by the

111 of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and Triplex in healthy adult

112 eminated viral disease in hematopoietic cell transplant (HCT) recipients but does not lead to resolut

113 nical and laboratory parameters, medical and transplant history from 977 prevalent kidney transplant

114 h a high flow state and/or increased volume, transplant hospitalization and 1-year posttransplant out

115 Primary and secondary outcomes were transplant hospitalization mortality and 1-year mortalit

116 Transplant hospitalization mortality was 0% for those wi

117 he major cause of late mortality after heart transplant (HT), there is a need to identify markers tha

118 s and microenvironment in lineage choice, we transplanted human hematopoietic stem and progenitor cel

119 enrolled in the Malnutrition-Inflammation in Transplant-Hungary study.

120 ported that embryonic motor cortical neurons transplanted immediately after lesions in the adult mous

121 Trial designs for new transplant immunosuppression must be intelligently restr

122 More than 40% of patients awaiting a kidney transplant in the UK are sensitised with human leucocyte

123 d a validation cohort of 98 heart recipients transplanted in Edmonton, AB, Canada, including 27 cases

124 letion of the microbiota, we performed fecal transplants in antibiotic-treated mice and found that tr

125 d with the waitlist including KDPI 0% to 85% transplants in patients older than 60 years.

126 an is a powerful approach to monitoring post-transplant injury.

127 At 6 months post-transplant, intervention participants reported lower dep

128 livers offered to children, 2533 (12%) were transplanted into children; 1179 of these (47%) were imm

129 Tgfb2-/- NPCs transplanted into EAE mice were ineffective in impairing

130 When region-specific organoids were transplanted into immunocompromised mice, duodenum-like

131 When transplanted into immunodeficient mice, FOXP3-expressing

132 reased BM trafficking and extravasation when transplanted into mice.

133 with constipation and healthy controls were transplanted into the antibiotic depletion mice model.

134 hology can manifest in healthy neural tissue transplanted into the brains of patients with two distin

135 from the fetal or postnatal mouse bowel and transplanted into the distal colon of 3- to 4-week-old w

136 Living donor pancreas transplant is a potential treatment for diabetic patient

137 Lower eGFR 1 year after kidney transplant is associated with shorter allograft and pati

138 ival rate of HLA poorly matched living donor transplants is not inferior to that of HLA well-matched

139 The transplanted islets successfully normalized and maintain

140 Among the 12,831 DCD kidneys transplanted, kidneys with WIT</=48 minutes had survival

141 nts' demographic, cultural, psychosocial, or transplant knowledge factors.

142 lder patients with ESRD who receive a kidney transplant (KT) may develop post-KT dementia and Alzheim

143 ies have described ED use rates among kidney transplant (KTx) recipients, and the factors associated

144 d reverse genetics were used to sequentially transplant larger portions of the DENV3-specific 5J7 mAb

145 hemoglobin [HbA1c]) and survival in all lung transplant (LTx) recipients and those with either persis

146 the Norwegian Renal Registry with all renal transplanted men alive between January 1, 1995 and Decem

147 remained (a) whether the plaque phenotype in transplanted mice resulted from a genuine effect of Trpc

148 In a skin transplant model, the addition of IL-2 synergizes with C

149 ry in DCD renal allografts in a large animal transplant model.

150 st disease (GvHD) in both murine preclinical transplant models and in human clinical trials while mai

151 Transformation of the surface of the transplanted myofascial flap was analyzed in the airway

152 r immune response and higher survival of the transplanted neurons.

153 Transplanted NMP grafts were matched 1:3 with transplant

154 ts in antibiotic-treated mice and found that transplant of fecal material from an untreated mouse abo

155 Some mice were irradiated and given transplants of bone marrow cells from C57BL6 mice, with

156 to quartiles of risk of mortality and kidney transplant on the basis of multivariable Cox modeling.

157 We found that primary ALL cells transplanted onto nonobese diabetic/severe combined immu

158 efficiently allocate resources, and increase transplant opportunities.

159 /-2.4 years, the primary end point of death, transplant, or admission for heart failure was reached i

160 d the composite rates for death, double-lung transplant, or restenosis at 36 months were 5% and 30%,

161 (cfDNA) in circulating blood derived from a transplanted organ is a powerful approach to monitoring

162 the distinct immunological features of each transplanted organ, Treg preparations, dose, and frequen

163 with that seen in wild-type bone marrow (BM)-transplanted OS mice in peripheral blood and hematopoiet

164 rs for ZIKV infection among organ donors and transplant outcomes among recipients of donors with posi

165 the first time poorer waitlist and postliver transplant outcomes in young adults ages 18 to 24 years

166 an is not stopped, thus resulting in optimal transplant outcomes.

167 ed eplet loads affect antibody responses and transplant outcomes.

168 week (UNOS-DGF), associates with poor kidney transplant outcomes.

169 esents a novel clinical target for improving transplant outcomes.

170 Finally, participants transplanted over 11 y ago showed the highest levels of

171 Cystic lesions of the transplant pancreas developed in 22 patients (1.8%): 12

172 from patients with BOS (n = 10), stable lung transplant patients (n = 18), and healthy aged-matched c

173 in the bronchoalveolar lavage fluid of lung transplant patients diagnosed with IA that received casp

174 Data from 266 pancreas transplant patients including 182 simultaneous kidney-pa

175 creening for urologic malignancies in kidney transplant patients is warranted, and as such, this revi

176 entage of Foxp3+ regulatory T cells in liver transplant patients was stable in the study period.

177 safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV infection.

178 Solid organ transplant patients with first episode of CMV disease or

179 ession by T cells and infectious episodes in transplant patients.

180 association with renourinary malignancies in transplant patients.

181 t rejection and lead to better therapies for transplant patients.

182 e assessed the outcome of all (n = 95) renal transplanted patients with pretransplant cancer diagnose

183 the standard risk donors (3.9 vs 4.2 organs transplanted per donor).

184 ABO-incompatible renal transplant performed with antibody removal and conventio

185 Solitary kidney, liver, heart, and lung transplants performed between January 1, 2011, and Janua

186 Kidney transplants performed for pediatric recipients (age, <18

187 acted for 12 902 deceased-donor kidney alone transplants performed in all 19 English transplant centr

188 We compared transplants performed with robotic technique (RKT) versu

189 Of the 101 238 liver transplants performed, 61 were related to IBDI.

190 bility with human blood, suggesting that pre-transplant perfusion of genetically modified porcine org

191 del, pharmacokinetics of PGZ from fat depots transplanted perivascular to jugular vein were assessed

192 in the field of transplantation will require transplant physicians to embrace the increased complexit

193 us (HCV) infection is prevalent in the renal transplant population but direct acting antiviral agents

194 , and represents a leading malignancy in the transplant population.

195 her control group comprised the entire renal transplanted population in Uppsala.

196 is an inevitable event in conventional organ transplant procedure and is associated with significant

197 te of infection by the same pathogen in both transplant procedures.

198 Interestingly, PV- and SST-enriched transplants produced differential effects on behavior, w

199 ishing and directing the first Swedish heart transplant program.

200 one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bleeding

201 re 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage

202 the results in a cohort of 10 stable kidney transplant recipients (median of 4.3 years posttransplan

203 increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the

204 Solid organ transplant recipients (SOTR) with a pretransplant malign

205 ctive clinical study including healthy heart transplant recipients 6 months to 25 years of age presen

206 diatric and adolescent deceased donor kidney transplant recipients aged 21 years or younger using Aus

207 Transplant recipients and other immunocompromised hosts

208 Solid organ transplant recipients are at increased risk for developi

209 ximately 800 patients in the cohort of renal transplant recipients at our institution, 15 subjects we

210 e integrated national Scientific Registry of Transplant Recipients data (1987-2015) with records from

211 Using Scientific Registry of Transplant Recipients data from June 2013 to June 2015,

212 We used Scientific Registry of Transplant Recipients data to compare patients listed wi

213 profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Tolerance N

214 transplant history from 977 prevalent kidney transplant recipients enrolled in the Malnutrition-Infla

215 ational data registry used a cohort of renal transplant recipients from the United States Renal Data

216 The risk of graft failure in young kidney transplant recipients has been found to increase during

217 ta System records of Medicare-insured kidney transplant recipients in 2000 to 2011 to determine clini

218 but the optimal vaccination schedule in lung transplant recipients is unknown.

219 Thus, immunosuppressive strategies for lung transplant recipients need to be tailored based on the u

220 In this retrospective study of US kidney transplant recipients undergoing PCI, DES was associated

221 Medical records of the donor and infected transplant recipients were reviewed for clinical charact

222 crossmatch positive living donor HLAi kidney transplant recipients who received their transplant betw

223 Kidney transplant recipients with a pretransplant cancer had a

224 Organ transplant recipients with CF should initiate CRC screen

225 hort course (in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 IU/mL p

226 immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-sofosbuvir at our

227 Among renal transplant recipients with STEMI, the use of reperfusion

228 Kidney transplant recipients with urinary angiogenin amounts in

229 g-term hematopoietic stem cells in secondary transplant recipients, and enhanced survival of mice aft

230 in healthy, immunocompetent individuals, in transplant recipients, and in PTLD patients.

231 s known to have suboptimal immunogenicity in transplant recipients.

232 second leading cause of graft loss in kidney transplant recipients.

233 loped and validated for the UK population of transplant recipients.

234 V and urothelial carcinogenesis among kidney transplant recipients.

235 a (NPC), and lymphomas that develop in organ transplant recipients.

236 nct immunosuppressive therapy in solid organ transplant recipients.

237 iated with adverse outcomes in stable kidney transplant recipients.

238 ut their association with outcomes in kidney transplant recipients.

239 h advanced chronic kidney disease and kidney transplant recipients.

240 antibodies (non-HLAabs) were screened in 29 transplant recipients.

241 portant causes of morbidity and mortality in transplant recipients.

242 mpact of pretransplant sensitization on lung transplant recipients.

243 treatment of urologic malignancies in kidney transplant recipients.

244 and are capable of inducing AML in serially transplanted recipients.

245 Based on an analysis of 542 pediatric kidney transplants recorded by the UK Transplant Registry from

246 analyses were performed on first-time liver transplant registrants (n = 13 979) and recipients (n =

247 deceased donors with ITP recorded in the UK Transplant Registry between 2000 and 2015 were reviewed.

248 UK Transplant Registry data were collected on deceased dono

249 iatric kidney transplants recorded by the UK Transplant Registry from 2000 to 2012, it was concluded

250 05) for FED and BK from the Singapore Cornea Transplant Registry performed from 1991 to 2011.

251 m the Australia and New Zealand Dialysis and Transplant Registry, we examined the association between

252 using Australia and New Zealand Dialysis and Transplant registry.

253 uction could also enable novel therapies for transplant rejection and autoimmune diseases.

254 nting cells (APCs) play an important role in transplant rejection and tolerance.

255 allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progression and

256 egalovirus, and/or adenoviral infections and transplant-related mortality at 1 year were 4.2% +/- 4.1

257 ignificance of circulating antibodies before transplant remains unclear.

258 he Center for International Blood and Marrow Transplant Research or Eurocord and European Group for B

259 ed a unique approach to protect the heart by transplanting respiration-competent mitochondria to the

260 x, Risk Estimation of Tumor Recurrence After Transplant (RETREAT), which incorporates alpha-fetoprote

261 Differentiated and transplanted RGC-like cells derived from stem cells have

262 ransplanted NMP grafts were matched 1:3 with transplanted SCS livers.

263 001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor overall surv

264 herapies currently in clinical trials in the transplant setting include keratinocyte growth factor, c

265 nate only a few axons in the vicinity of the transplant site.

266 Solid organ transplant (SOT) recipients are at risk of nocardiosis,

267 Transplanted Sox10(+) stem cells differentiated into smo

268 ol group was obtained from the Collaborative Transplant Study registry and included European patients

269 Ventilation >7 days was associated with poor transplant suitability (P = .04).

270 OPD was not found to be associated with poor transplant suitability (P = .22).

271 Ventilation time >7 days affected transplant suitability but the presence of COPD did not.

272 The American Society of Transplant Surgeons (ASTS) PROviding better Access To Or

273 A-CIC were quantified immediately before the transplant surgery and patients were followed up for 6 m

274 Transplant survival was 93%, 90%, and 88% at 3, 6, and 1

275 ore frequently before or within a week after transplant than at later time points (P = 0.008).

276 Here we show that transplanting the pore domain of TRPV1 into Shaker gives

277 cystic fibrosis who never received an organ transplant; this strategy prevented 79% of deaths from C

278 mation of portal vein, and 3 (3.1%) had post-transplant thrombosis.

279 er deceased donor but not living donor renal transplants, thus donor death and organ preservation-rel

280 nvasive window into the conditional state of transplant tissue.

281 We hypothesized that transplanted tissues release donor-specific exosomes int

282 nal transplantation was associated with post-transplant TMA.

283 al surgery (GS), surgical oncology (SO), and transplant (TS).

284 This study aimed to determine effects of transplanted unmodified human bone marrow CD34+ (hBM34+)

285 From the UK adult kidney transplant waiting list, we selected crossmatch positive

286 ve difference in graft survival 1 year after transplant was 115 years, and by 5 years, the difference

287 PreKT and non-preKT KDPI greater than 85% transplant was associated with lower mortality hazard af

288 At baseline and 6 months post-transplant, we assessed mood, PTSD symptoms, and QOL wit

289 At the time of kidney transplant, we obtained and analyzed the sections of a b

290 nation haploidentical single-unit cord blood transplants, we have added 4 Gy TBI to the widely used f

291 ctors, differences in time to acceptance for transplant were explained by patients' demographic, cult

292 rolimus/mycophenolate regimens, and nonrenal transplants were excluded.

293 aneous kidney-pancreas and 84 pancreas alone transplants were reviewed for the study.

294 For adults with T2 HCC awaiting LT, transplant with any bridging therapy showed a nonsignifi

295 nuria was also measured in ABIN1[D485N] mice transplanted with WT mouse bone marrow.

296 identified 12,958 patients listed for liver transplants with HCC exception points from 2006 to 2013,

297 r not a surgeon accepts an offered liver for transplant, with a marked fall in acceptance rates for l

298 ents with end-stage heart failure at time of transplant, with or without diabetes mellitus.

299 prevalent ESRD in each facility referred for transplant within 1 year as the primary outcome, and dis

300 ied porcine organs with CHC may benefit post-transplant xenograft function.